Adult Epilepsy Treatment

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom¹

Fewer than 1 in 10 patients achieves seizure freedom with an anti-seizure medication (ASM) after 2 or more failures

ASM intolerance is one of the strongest and most consistent negative predictors of QoL for patients with DRE and is associated with behavioral and adverse events^2,4

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years^5,6

34% of patients were seizure free from their focal impaired awareness-motor seizures (N=160)

49% of patients were free from their focal to bilateral tonic-clonic seizures (N=92)

Focal impaired-aware motor seizures were reduced from baseline by a median of 80% at 36 months (N=160)

Focal to bilateral tonic-clonic seizures were reduced from baseline by a median of 95% at 36 months (N=92)

Epilepsy (US) – The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.

VNS Therapy^™ Safety Profile

The most common side effects of VNS Therapy include:

Hoarseness
Shortness of breath
Sore throat
Coughing

These side effects generally only occur during stimulation and usually decrease over time.

Infection is the most common side effect of the procedure.

You can find more safety information here.

References: 1. ‎Thurman DJ, Logroscino G, Beghi E, et al. Epilepsia. 2017;58(1):17-26. 2. Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24-31. 3.‎ Data on file. Survey report. LivaNova USA, Inc. Houston, TX. October 2021. 4. Alsfouk BAAA, Brodie MJ, Walters M, et al. JAMA Neurol. 2020;77(5):574-581. 5. Chen Z, Brodie MJ, Liew D, et al. JAMA Neurol. 2018;75(3):279-286. 6. Hamilton P, Soryal I, Dhahri P, et al. Seizure. 2018;58:120-126. 7. Data on file. CORE-VNS Clinical Study Report, LivaNova, USA, Inc. Houston, TX. June 2025. 8. Elliot RE, Morsi A, Tanweer O, et al. Effectiveness of vagus nerve stimulation over time: review of 65 consecutive patients with treatment-resistant epilepsy treated with VNS >10 years. Epilepsy Behav. 2011;20(3):478-483. 9. Data on file. E-36, E-37 Pooled Calculations. LivaNova USA, Inc. Houston, TX. 2015. 10. Beaudreault CP, Chiang S, Sacknovitz A, et al. Association of reductions in rescue medication requirements with vagus nerve stimulation: results of long-term community collected data from a seizure diary app. Epilepsy Behav. 2024;159:1-7. 11. Ben-Menachem E. J Clin Neurophysiol. 2001;18(5):415 418. 12. Epilepsy Patient’s Manual for Vagus Nerve Stimulation, LivaNova, Inc., Houston, TX. 13. VNS Therapy System Epilepsy Physician’s Manual (US), April 2025, LivaNova USA, Inc. Houston, TX.

IMPLANT THE FUTURE OF SEIZURE CONTROL

Medication alone is not enough when managing drug-resistant epilepsy

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom¹

ASM intolerance is one of the strongest and most consistent negative predictors of QoL for patients with DRE and is associated with behavioral and adverse events^2,4

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years^5,6

VNS Therapy™ has been used to deliver life-changing treatment to more than 175,000 people with drug-resistant epilepsy, including 50,000+ children³

CORE‑VNS provides up‑to‑date insights on patient outcomes with VNS Therapy™ in today’s drug‑resistant epilepsy (DRE) landscape

In CORE-VNS, some patients experienced significant reductions in monthly seizure frequency and freedom from seizures, including the most severe types⁷

34% of patients were seizure free from their focal impaired awareness-motor seizures (N=160)

49% of patients were free from their focal to bilateral tonic-clonic seizures (N=92)

Focal impaired-aware motor seizures were reduced from baseline by a median of 80% at 36 months (N=160)

Focal to bilateral tonic-clonic seizures were reduced from baseline by a median of 95% at 36 months (N=92)

51% of patients were super responders (≥80% reduction in seizure frequency) for focal seizure types reported at baseline compared to 36 months (N=309)⁷

VNS Therapy^TM response improves over time with a 76% mean reduction in seizures at 10 years

VNS Therapy™ demonstrates improvements in quality of life (memory, seizure worry and mood)⁹

Improvements in quality-of-life confirmed across 2 prospective, multicenter, clinical trials (E-36) and (E-37)⁹

Rescue medication use significantly decreased after implantation of VNS Therapy^TM at 3 months and continued to decrease over time.¹⁰

VNS Therapy^TM Safety Profile

VNS Therapy is proven to be a safe adjunctive treatment and is well-tolerated by most patients without contributing to ASM toxicity.^11,12

The most common side effects of VNS Therapy occur during stimulation and generally become less noticeable over time for most patients.^11,13 Infection is the most common complication of the procedure.¹⁴

Implant the Future of Seizure Control

VNS Therapy^™ Safety Profile

Learn about SenTiva

Hear patient stories

Choose a country

For ALL other countries, please click here.

IMPLANT THE FUTURE OF SEIZURE CONTROL

Medication alone is not enough when managing drug-resistant epilepsy

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom1

ASM intolerance is one of the strongest and most consistent negative predictors of QoL for patients with DRE and is associated with behavioral and adverse events2,4

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years5,6

VNS Therapy™ has been used to deliver life-changing treatment to more than 175,000 people with drug-resistant epilepsy, including 50,000+ children3

CORE‑VNS provides up‑to‑date insights on patient outcomes with VNS Therapy™ in today’s drug‑resistant epilepsy (DRE) landscape

In CORE-VNS, some patients experienced significant reductions in monthly seizure frequency and freedom from seizures, including the most severe types7

34% of patients were seizure free from their focal impaired awareness-motor seizures (N=160)

49% of patients were free from their focal to bilateral tonic-clonic seizures (N=92)

Focal impaired-aware motor seizures were reduced from baseline by a median of 80% at 36 months (N=160)

Focal to bilateral tonic-clonic seizures were reduced from baseline by a median of 95% at 36 months (N=92)

51% of patients were super responders (≥80% reduction in seizure frequency) for focal seizure types reported at baseline compared to 36 months (N=309)7

VNS TherapyTM response improves over time with a 76% mean reduction in seizures at 10 years

VNS Therapy™ demonstrates improvements in quality of life (memory, seizure worry and mood)9

Improvements in quality-of-life confirmed across 2 prospective, multicenter, clinical trials (E-36) and (E-37)9

Rescue medication use significantly decreased after implantation of VNS TherapyTM at 3 months and continued to decrease over time.10

VNS TherapyTM Safety Profile

VNS Therapy is proven to be a safe adjunctive treatment and is well-tolerated by most patients without contributing to ASM toxicity.11,12

The most common side effects of VNS Therapy occur during stimulation and generally become less noticeable over time for most patients.11,13 Infection is the most common complication of the procedure.14

Implant the Future of Seizure Control

VNS Therapy™ Safety Profile

Learn about SenTiva

Hear patient stories

Choose a country

For ALL other countries, please click here.

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom¹

ASM intolerance is one of the strongest and most consistent negative predictors of QoL for patients with DRE and is associated with behavioral and adverse events^2,4

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years^5,6

VNS Therapy™ has been used to deliver life-changing treatment to more than 175,000 people with drug-resistant epilepsy, including 50,000+ children³

In CORE-VNS, some patients experienced significant reductions in monthly seizure frequency and freedom from seizures, including the most severe types⁷

51% of patients were super responders (≥80% reduction in seizure frequency) for focal seizure types reported at baseline compared to 36 months (N=309)⁷

VNS Therapy^TM response improves over time with a 76% mean reduction in seizures at 10 years

VNS Therapy™ demonstrates improvements in quality of life (memory, seizure worry and mood)⁹

Improvements in quality-of-life confirmed across 2 prospective, multicenter, clinical trials (E-36) and (E-37)⁹

Rescue medication use significantly decreased after implantation of VNS Therapy^TM at 3 months and continued to decrease over time.¹⁰

VNS Therapy^TM Safety Profile

VNS Therapy is proven to be a safe adjunctive treatment and is well-tolerated by most patients without contributing to ASM toxicity.^11,12

The most common side effects of VNS Therapy occur during stimulation and generally become less noticeable over time for most patients.^11,13 Infection is the most common complication of the procedure.¹⁴

VNS Therapy^™ Safety Profile